Latest Azacitidine Stories
A two-drug combination is safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients who are usually excluded from clinical trials because they have other illnesses or poor performance status - a measure of disease progression - researchers reported this week at the 52nd American Society of Hematology Annual Meeting.
PALO ALTO, Calif., Dec. 6, 2010 /PRNewswire/ -- Telik, Inc.
Chemical changes in the genetic material, known as epigenetic modifications, regulate the activity of many genes.
WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013 for the treatment of high-risk myelodysplastic syndromes.
The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., May 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2012, growth in the myelodysplastic syndromes drug market will be driven principally by the launch in Europe of Celgene's Vidaza and Revlimid.
VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence CROSSWICKS, N.J., Feb.
A French-led international study suggests acute myeloid leukemia patients treated with Vidaza (azacitidine) have significantly increased overall survival. Acute myeloid leukemia is a cancer in which abnormal cells accumulate in bone marrow and interfere with normal blood cell production.
Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec.
- a meat pie that is usually eaten at Christmas in Quebec